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A
C
DObjectives: The present systematic review objectively assessed the safety and clinical effectiveness of trans-
catheter aortic valve implantation for patients at high surgical risk with severe aortic stenosis.
Methods: Electronic searches were performed in 6 databases from January 2000 to March 2009. The end points
included feasibility, safety, efficacy, and durability. Clinical effectiveness was synthesized through a narrative
review with full tabulation of results of all included studies.
Results: The current evidence on transcatheter aortic valve implantation for aortic stenosis is limited to short-
term observational studies. The overall procedural success rates ranged from 74% to 100%. The incidence of
major adverse events included 30-day mortality (0%–25%), major ventricular tachyarrhythmia (0%–4%),
myocardial infarction (0%–15%), cardiac tamponade (2%–10%), stroke (0%–10%), conversion to surgery
(0%–8%), moderate to major paravalvular leak (4%–35%), vascular complication (8%–17%), valve-in-valve
procedure (2%–12%), and aortic dissection/perforation (0%–4%). The overall 30-day major adverse cardio-
vascular and cerebral events ranged from 3% to 35%. The mean aortic valve area ranged from 0.5 to 0.8
cm2 before and 1.3 to 2.0 cm2 after transcatheter aortic valve implantation. The mean pressure gradient ranged
from 34 to 58 mm Hg before and 3 to 12 mm Hg after transcatheter aortic valve implantation. There was no
significant deterioration in echocardiography measurements during the assessment period. Death rate at 6 months
postprocedure ranged from 18% to 48%. No studies had adequate follow-up to reliably evaluate long-term
outcomes.
Conclusions: The procedure has a potential for serious complications. Although short-term efficacy based on
echocardiography measurements is good, there is little evidence on long-term outcomes. The use of transcatheter
aortic valve implantation should be considered only within the boundaries of clinical trials. (J Thorac Cardiovasc
Surg 2010;139:1519-28)Aortic stenosis (AS) is the most common valvular heart dis-
ease in adults.1 The disorder is becoming more frequent as
the age of the population increases, representing a growing
public health issue. Severe AS is universally fatal if left un-
treated, with three-quarters of patients dying within 3 years
of symptom onset.2 No medical treatment improves survival
in chronic disease, as the obstruction to outflow tract requires
mechanical relief. Mortality rates are significantly reduced in
symptomatic patients with AS by aortic valve replacement
(AVR).3 Thus, AVR can be withheld in such patients only
when compelling contraindications exist. A recent prospec-
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The Journal of Thoracic and CarEurope suggests that almost one-third of patients over the
age of 75 with severe AS do not undergo AVR, due to risks
arising from age and comorbidities.1 These findings have
stimulated tremendous interest in reducing patient morbidity
and mortality and motivated the development of a less-inva-
sive transcatheter aortic valve (TAV) procedure.4-31
The analysis of The Society of Thoracic Surgeons
National Cardiac Database evidenced that, among 46,397
patients, mortality for surgical AVR ranges from 4.3% for
first isolated AVR to 25% for redo surgery or multiple valve
replacement plus coronary artery bypass grafting, with an
overall mortality rate of 6.4%.32 Fish33 states that surgical
results are excellent even in high-risk patients and that adop-
tion of a percutaneous approach must be justified and guar-
antee high performance. Many issues related to TAV
implantation remain to be clarified by clinical data. We per-
formed the present systematic review to objectively assess
the safety and clinical effectiveness of TAV implantation
in treatment of severe AS.
METHODS
Literature Search Strategy
Electronic searches were performed in 6 databases from January 2000 to
March 2009: MEDLINE, EMBASE, PubMed, Cochrane Central Registerdiovascular Surgery c Volume 139, Number 6 1519
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Acquired Cardiovascular Disease Yan et al15Abbreviations and Acronyms20AS ¼ aThe Jortic stenosisAVR ¼ aortic valve replacement
MACCE ¼ major adverse cardiovascular and
cerebral eventsNYHA ¼ New York Heart Association
SD ¼ standard deviation
TAV ¼ transcatheter aortic valveof Controlled Trials, Cochrane Database of Systematic Reviews, and Data-
base of Abstracts of Review of Effectiveness. To achieve the maximum sen-
sitivity of the search strategy and identify all studies, we used appropriate
free text and thesaurus terms: ‘‘percutaneous’’ OR ‘‘transcutaneous’’ OR
‘‘transcatheter’’ OR ‘‘transarterial’’ OR ‘‘transapical’’ AND ‘‘aortic
valve’’ OR ‘‘aortic valve stenosis.’’ The reference lists of all retrieved arti-
cles were reviewed for further identification of potentially relevant studies.
Study Population
The study population was defined as patients of high surgical risk with
AS or those deemed not suitable for surgical AVR, whereas TAV implan-
tation was considered. The criteria for patient selection for TAV implanta-
tion varied among institutions, and the definitions for nonsurgical
candidates were not uniform.
Interventions
The balloon-expandable TAV consists of 3 pericardial leaflets, initially
equine (Cribier-Edwards; Edwards Life Sciences Inc, Irving, Calif) and
currently bovine (Edwards-Sapien; Edwards Life Sciences), mounted within
a tubular, slotted, stainless steel balloon-expandable stent. Initial devices
were 14 mm in length and 23 mm in expanded diameter, with a larger device
available subsequently (length 16 mm, expanded diameter 26 mm). Current
devices require either a 22F or 24F (transfemoral) or 26F (transapical) sheath
for delivery. Three different insertion techniques have been used for Edwards
TAV: the original antegrade approach where the TAV is delivered via the
venous route; the retrograde approach by which it is delivered via an arterial
route; and the transapical route requiring aminithoracotomy for delivery of the
device via the apex of the left ventricle. The self-expandable percutaneous
aortic valve (CoreValve; CoreValve, Irving, Calif) consists of 3 pericardial
tissue leaflets, initially bovine and currently porcine, mounted and sutured
in a self-expandable nitinol stent. The available valve diameters are 22 and
26mm. Early devices required 25F sheaths. Second-generation devices incor-
porated porcine pericardial tissue that allowed decrease in profile to 21F
sheaths. The current device was further redesigned in the fixing of the valve
tissue onto the stent, decreasing the profile to 18F sheaths.
Outcome Measures
The findings from initial scoping searches were used in deciding which
outcomes to include in the present review. The primary end points included
feasibility and safety (procedural success rate, 30-day mortality, major
tachyarrhythmia, bradyarrythmia requiring permanent pacemaker insertion,
myocardial infarction, cardiac tamponade, cerebrovascular accident, con-
version to surgery, conversion to valvuloplasty, vascular complication,
moderate to severe paravalvular leak, valve-in-valve procedure, emergency
percutaneous coronary intervention, endocarditis, aortic dissection/perfora-
tion, blood transfusion>2 U, procedure duration, and length of hospital
stay). The secondary outcomes included efficacy and durability based on
echocardiographic findings and clinical outcomes at 1, 6, and 12 months
(mean aortic valve area before and after TAV implantation, peak and
mean pressure gradient before and after TAV implantation, left ventricularournal of Thoracic and Cardiovascular Surejection fraction before and after TAV implantation, NewYork Heart Asso-
ciation [NYHA] functional class improvement versus baseline, numbers of
patients at risk at 6-month and 12-month reviews, and number of patients
deceased at 6-month follow-up).
Study Design and Selection Criteria
Ameta-analysis was not appropriate because no comparisons among dif-
ferent devices or techniques of insertion have been reported, and the poten-
tial differences in prostheses might exist. Experimental or observational
studies were included in the present review. Case reports, abstracts, edito-
rials, and expert opinions were excluded. Studies eligible for this systematic
review included high-risk patients with AS who received TAV implanta-
tion. When centers had published duplicate trials with accumulating num-
bers of patients or increased lengths of follow-up, only the most complete
reports were included for qualitative appraisal and data extraction.
Data Extraction and Critical Appraisal
The 2 investigators (T.D.Y. and R.P.) independently appraised each in-
cluded article, using a critical review checklist as recommended by the Na-
tional Health Service Center for Reviews and Dissemination case series
quality assessment criteria (University of York).34 This consisted of repre-
sentativeness of study sample, explicitness of inclusion criteria, similarity of
disease progression at the time of treatment, adequacy of follow-up, objec-
tivity of outcome measures, and appropriateness of subseries analysis. The
criteria for assessing the quality of morbidity andmortality data included the
following 4 points: whether there was an adequate explanation of how ad-
verse effects were identified; whether a standardized or validated measure-
ment instrument was used; how the adverse effect(s) was attributed to the
intervention; and whether the terms were clearly explained.
All data were extracted from the relevant articles’ texts, tables, and fig-
ures. Clinical effectiveness was synthesized through a narrative review with
full tabulation of results of all included studies. Discrepancies between the 2
reviewers were resolved by discussion and consensus with a third investiga-
tor (J.M.-N.). The final results were reviewed by all 3 senior investigators
(M.N., M.P.V., and P.G.B.).
RESULTS
Quantity of Studies
The titles and abstracts of 571 peer-reviewed publications
were identified through searching the 6 electronic databases.
Initial evaluation of these abstracts identified 57 potentially
relevant publications. Manual search of the reference lists
identified 4 additional publications of interest. When the in-
clusion and exclusion criteria were applied to these 61 pub-
lications, 28 articles4-31 remained for assessment (Table 1).
Serial publications reporting accumulating numbers of pa-
tients or increased length of follow-up were identified. The
publication with most complete data set from each center
was retained. In total, 17 studies were included for appraisal
and data extraction (Table 2).6,9,11-13,16,18-23,25,27,29-31 All
studies evaluated the feasibility and safety of TAV implan-
tation. All except 1 study23 assessed the efficacy and durabil-
ity of TAV using hemodynamic measurements by use of
echocardiography.
Quality of Studies
No randomized controlled trials or matched comparative
studies were identified. All 17 included articles were experi-
mental studies without control groups.6,9,11-13,16,18-23,25,27,29-31gery c June 2010
TABLE 1. Summary of outcomes presented in relevant publications on transcatheter aortic valve implantation for high-risk patients with aortic stenosis
Treatment
center Reference Year n
Success
rate
Post-TAV
mortality
Post-TAV
morbidity
Myocardial
infarction
Emergency
cardiac
surgery
Cerebrovascular
accident
Blood
transfusion
Length of
hospital
stay
Echocardiography
findings
NYHA
functional
class
Learning
curve Survival
Antegrade Edwards valve
Rouen, France 4 2004 6 C C C C
5 2004 8 C C
6 2006 36 C C C C C C C C
7 2007 36 C C C C C
Retrograde Edwards valve
Vancouver, Canada 8 2006 18 C C C C C C C C C C
9 2007 50 C C C C C C C C C C C
10 2008 40 C C C C C C C
Paris, France 11 2008 12 C C C C C C C C C C
Athens, Greece 12 2008 12 C C C C C C
Quebec, Canada 13 2008 24 C C C C C C C C C
Transapical Edwards valve
Vancouver, Canada 14 2006 7 C C C C C C
15 2007 7 C C C C C C C C
16 2009 26 C C C C C C C C C C
Leipzig, Germany 17 2007 30 C C C C C C C C
18 2008 50 C C C C C C C C
Frankfurt, Germany 19 2008 26 C C C C C C C
Multicenter 20 2007 59 C C C C C C
Bicenter 21 2008 40 C C C C C C C C C
CoreValve retrograde valve
Siegburg, Germany 22 2006 25 C C C C C C C C
Brighton, UK 23 2008 12 C C C
Montreal, Canada 24 2007 10 C C C C C C C C C C
25 2007 13 C C C C C C C C C C
26 2008 13 C C C C C
Rotterdam,
Netherlands
27 2008 33 C C C
28 2008 39 C C
Catania, Italy 29 2009 30 C C C C C C C C C
Multicenter 30 2007 86 C C C C C C C
Multicenter 31 2008 646 C C C C C C C
TAV, Transcatheter aortic valve.
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TABLE 2. Summary of the 17 trials included in the present systematic review
Study
Referred
(n)
Attempted
(n) Study period
Age
(mean ± SD)
Logistic
EuroSCORE
(mean ± SD) Procedure
Procedural success,
n (%)
Antegrade Edwards valve
Rouen, France6 36 33 2003–2005 80  7 12  2 LA/sedation,
antegrade (26);
retrograde (7); rapid
ventricular pacing;
no CPB
27 (82)
Retrograde Edwards valve
Vancouver, Canada9 — 50 2005–2006 82  7 28 GA; retrograde;
rapid ventricular
pacing; no CPB
43 (86)
Paris, France11 39 12 2006–2007 85  6 31  14 GA; retrograde, rapid
ventricular pacing
10 (83)
Athens, Greece12 — 12 2007–2008 81  5 34  15 GA; retrograde (8);
transapical (4);
rapid ventricular
pacing; by
cardiologists and
cardiac surgeons
12 (100)
Quebec, Canada13 29 22 2007–2008 84  7 26  16 GA; retrograde (11);
apical (11); rapid
ventricular pacing;
by cardiologists
and cardiac surgeons
20 (91)
Transapical Edwards valve
Vancouver, Canada16 — 26 2005–2007 80  9 37  20 GA; minithoracotomy;
transapical; rapid
ventricular
pacing; by cardiac
surgeons
26 (100)
Leipzig, Germany18 83 50 2006–2007 82  5 28  12 47 (94)
Frankfurt, Germany19 — 26 2006–2008 84  7 37  6 26 (100)
Multicenter20 — 59 2006 81  6 27  14 55 (93)
Bicenter21 163 40 2006–2008 83  8 36  15 35 (88)
Retrograde CoreValve valve
Siegburg, Germany22 25 25 2005 80  5 11* GA; retrograde; 24 and
21F sheaths;
fem-fem CPB
21 (84)
Brighton, UK23 — 12 2007–2008 80* 22* GA (3); LA/sedation
(9); retrograde; 18F
sheaths; rapid
ventricular pacing
12 (100)
Montreal, Canada25 29 11 2005–2006 82  7 36* GA; retrograde; CPB 11 (100)
Rotterdam, Netherlands27 — 33 2005–2007 81  7 20  12 Retrograde; rapid
ventricular pacing;
21 and 18F sheaths;
 CPB
33 (100)
Catania, Italy29 69 30 2007–2008 82  5 25  8 LA/sedation or GA,
retrograde; 18F; rapid
ventricular pacing
28 (93)
Multicenter30 — 86 2005–2007 82  6 22  13 GA or LA/sedation;
retrograde; 21F and
18F sheaths; 
fem-fem CPB
64 (74)
Multicenter31 — 646 2007–2008 81  7 23  14 LA/sedation or GA,
retrograde; 18F; rapid
ventricular pacing
628 (97)
CPB, Cardiopulmonary bypass; GA, general anesthetic; LA, local anesthetic; fem, femeral. *Median.
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Yan et al Acquired Cardiovascular DiseaseAll reports originated from specialized tertiary referral centers.
Five series had50patients (range, 50–646),9,18,20,30,31 and the
remaining 12 series had <50 patients (range, 11–40).6,11-
13,16,19,21-23,25,27,29 The definitions of high-risk patients with
AS not suitable for surgicalAVRvaried among the institutions.
For example, age>70,11,21>75,18-20,31>8025,30; NYHA func-
tional class III/IV6,11,12; AVA <1 cm2,22,29-31<0.8
cm2,12,19<0.7 cm2,6,11<0.6 cm2,21,25; logistic EuroSCORE
>20%,11,12,19,25,30 additive EuroSCORE 9,18,20 Society of
Thoracic Surgeons score>15%,21 and Parsonnet’s 30.6
In 16 studies,6,9,11-13,16,18-23,25,27,29,30 the number of pa-
tients evaluated was relatively small and the patients were
highly selected. The study sample in these 16 series was un-
likely to be fully representative of the study population and
was not large enough to provide definitive estimates of inci-
dence of all adverse events. It is acknowledged that the lack
of evidence of a rare adverse effect is not proof that such an
adverse effect is not associated with the procedure. One mul-
ticenter study assessed the procedural and 30-day outcomes
of 18F CoreValve in 646 patients.31 Thirteen studies re-
ported explicit priori inclusion criteria,6,11,12,18-22,25,27,29-31
and 4 studies did not.9,13,16,23 All studies reported proce-
dure-related or 30-day morbidity and mortality.6,9,11-13,
16,18-23,25,27,29-31 Ten studies reported follow-up data at 6
months.6,9,11,13,16,18,20,22,25,29 Eight studies reported fol-
low-up data at 12 months.6,9,16,18,20,22,25,29 Two studies
had follow-up data on 2 and 3 patients beyond 2 years, re-
spectively.2,16 No studies provided adequate long-term fol-
low-up data. All but 1 study23 evaluated hemodynamic
measurements by echocardiography. Blinding was not re-
ported. Three studies performed subgroup analysis assessing
procedural learning curve.9,18,30 Morbidity, mortality, he-
modynamic measurements, and survival rates were objec-
tive outcome measures.
All studies clearly defined the techniques of TAV inter-
vention, and there was reasonable consistency in the descrip-
tion of the techniques used for each approach. Clinical
adverse events were adjudicated by an independent clinical
committee in 3 studies,22,29,30 not in 3 other studies,9,16,31
and not reported in the remaining 11 studies.6,11,12,16,18-21,
23,25,27 The duration of follow-up was reported in 14
studies6,9,11-13,16,18-22,25,29,30 and not in 3 studies.23,27,31
Six studies reported data according to periprocedural
major adverse cardiovascular and cerebral events
(MACCE).6,21,22,29-31 In 11 studies, no standardized
measurement instrument was used for reporting adverse
events.9,11-13,16,18-20,23,25,27 The definitions of adverse
events were clearly explained in 8 studies6,9,16,21,22,29-31
and not in 9 studies.11-13,18-20,23,25,27
Assessment of Feasibility
The overall procedural success rates ranged from 74% to
100% (Table 2).6,9,11-13,16,18-23,25,27,29-31 Cribier and associ-
ates6 reported that 22 of the 26 antegrade implantationsThe Journal of Thoracic and Car(85%) of Edwards TAV were performed successfully with
4 technical failures. Two of these patients did not hemody-
namically tolerate the guide wire across the mitral valve.
In the other 2 patients, valve migration occurred immedi-
ately after implantation.
With the retrograde implantation of the Edwards prosthe-
sis, Webb and colleagues9 achieved successful implantation
in 43 patients (86%). Reasons for failure included inability
to pass through the iliac artery (n ¼ 1) and cross the aortic
valve (n ¼ 3), a defective prototype delivery catheter (n ¼
1), and malpositioning (n ¼ 2). Descoutures and co-
workers11 reported procedural success in 10 of 12 patients
(83%). Reasons for failure included inability to pass though
the iliac artery (n ¼ 1) and intraprocedural death from
hemopericardium, because of perforation of the left ventricle
by the wire (n ¼ 1). Rodes-Cabau and colleagues13 reported
that procedural success was obtained in all but 2 patients
(91%). One transfemoral procedure was aborted due to
severely calcified femoral arteries, and the other patient died
during the procedure, presumably from ischemic heart
disease.
With the transapical approach, 2 single-institutional
studies reported 100% success rate.16,19 Walther and as-
sociates18 reported that 47 of 50 patients (94%) had
successful implantation, with 3 patients requiring early
conversion to open AVR. One multicenter study from
Leipzig, Vienna, Frankfurt, and Dallas20 reported suc-
cessful transapical valve positioning in 55 patients
(93%) with the remaining 4 patients requiring conversion
to sternotomy, as the valves were incorrectly positioned.
In a bicenter study from Dallas and Cleveland,21 35 of
the 40 TAVs (88%) were successfully seated. Two valves
embolized and required open AVR, and 1 case of severe
regurgitation later required AVR. Two additional patients
required cardiopulmonary support: 1 valve later embol-
ized and 1 migrated.
With the CoreValve prosthesis, 3 studies reported
100% success rate.23,25,27 Grube and colleagues22 reported
acute procedural success achieved in 21 of 25 patients
(84%). In 2 patients, significant paravalvular leakage
occurred, requiring open AVR. In 1 patient, the device
could not cross the heavily calcified native valve and the
patient died suddenly 12 hours after the balloon valvulo-
plasty. One additional patient died on the second postpro-
cedural day after successful device implantation as a result
of delayed pericardial tamponade secondary to wire perfo-
ration of the left ventricle. Tamburino and coworkers29
achieved procedural success in 28 of 30 patients (93%),
with 1 malpositioning of the prosthesis requiring
a valve-in-valve procedure, and another patient sustained
a nonfatal pericardial tamponade. In the multicenter study
from Siegburg, Leipzig, and Montreal, acute device suc-
cess was achieved in 76 of 86 patients (88%), but the pro-
cedural success was 74%.30 In 6 patients, misplacement ofdiovascular Surgery c Volume 139, Number 6 1523
TABLE 3. Procedural and 30-d clinical outcomes following transcatheter aortic valve implantation
Study n
Death at
30 d, n (%)
Major
tachyarrhythmia,
n (%)
Pacemaker
insertion,
n (%)
Myocardial
infarction,
n (%)
Cardiac
tamponade,
n (%)
Cerebrovascular
accident, n (%)
Conversion
to surgery,
n (%)
Antegrade Edwards valve
Rouen6 33 6 (18) 1 (3) 1 (3) 0 2 (6) 1 (3) 0
Retrograde Edwards valve
Vancouver9 50 6 (12) 2 (4) 2 (4) 1 (2) 1 (2) 2 (4) 0
Paris11 12 3 (25) — 1 (8) 0 1 (8) 0 0
Athens12 12 0 — — — — — —
Quebec13 22 2 (9) 1 (5)* 0 0 1 (5) 0 1 (5)
Transapical Edwards valve
Vancouver16 26 6 (23) 0 3 (12) 1 (4) — 1 (4) 0
Leipzig18 50 4 (8) — — — — — 3 (6)
Frankfurt19 26 4 (15) 5 (19)* — — — 0 2 (8)
Multicenter20 59 8 (14) 18 (31)* — — — 2 (3) 4 (7)
Bicenter21 40 7 (18) — — 6 (15) — 2 (5) 2 (5)
Retrograde CoreValve valve
Siegburg22 25 5 (20) 0 — 0 1 (4) 1 (4) 2 (8)
Brighton23 12 1 (8) - 3 (25) — — — —
Montreal25 11 2 (18) - 4 (36) — — 1 (9) 0
Rotterdam27 33 2 (6) - — — 1 (3) — —
Catania29 30 2 (7) 0 — 0 1 (3) 0 0
Multicenter30 86 10 (12) - — 1 (1) 9 (10) 9 (10) 6 (7)
Multicenter31 646 52 (8) - 60 (9) 4 (1) 9 (1) 12 (2) 3 (1)
SD, Standard deviation. *Supraventricular arrhythmia. yMean.
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patients, the device did not cross heavily calcified native
valves despite balloon predilatation. In 2 patients, subopti-
mal placement of the prosthesis resulted in aortic regurgi-
tation, requiring implantation of a second CoreValve
prosthesis. Finally, the largest collaborative study on 646
patients who had 18F CoreValve implantation demon-
strated a procedural success in 97% of the patients, and
the details of failure were not provided.31
Assessment of Safety
Table 3 demonstrates 30-day major cardiovascular and
cerebral adverse events following TAV across all stud-
ies.6,9,11-13,16,18-23,25,27,29-31 The range of these adverse
events was as following: 30-day mortality (0%–25%); ma-
jor ventricular tachyarrhythmia (0%–4%); supraventricular
tachyarrhythmia (5%–31%); bradyarrhythmia requiring
permanent pace maker insertion (0%–36%); myocardial
infarction (0%–15%); cardiac tamponade (2%–10%);
cerebrovascular accident (0%–10%); conversion to sur-
gery (0%–8%); conversion to valvuloplasty (0%–4%);
vascular complication (8%–17%); moderate to major
paravalvular leak (4%–35%); valve-in-valve procedure
(2%–12%); emergency percutaneous coronary interven-
tion (0%–8%); endocarditis (0%); aortic dissection/rup-
ture (0%–4%); and blood transfusion>2 U (3%–24%).
The mean procedure duration varied from 2.5 to 2.9 hours.
The mean length of hospital stay ranged from 7 to 17 days.1524 The Journal of Thoracic and Cardiovascular SurThe overall 30-day MACCE ranged from 3% to
35%.6,21,22,29-31
Assessment of Efficacy
The efficacy of TAV implantation was assessed based on
echocardiographic findings (Table 4).6,9,11-13,16,18-23,25,27,29-31
One study23 did not report echocardiographic measure-
ments. The remaining 16 studies6,9,11-13,16,18-22,25,27,29-31
all demonstrated significant improvement in hemodynamic
performance (P < .05) when comparing preprocedural
with postprocedural (in-hospital) echocardiography mea-
surements. Left ventricular ejection fraction ranged from
41% to 56% before and 46% to 63% after TAV implan-
tation.
Assessment of Durability
Fifty percent to 100% of patients had improved NYHA
functional class at least by 1 grade at 1-month follow-
up.6,9,12,13,16,21,22,30 As stated before, no studies had ade-
quate follow-up to reliably evaluate long-term outcomes.
Follow-up echocardiographic findings were available in 9
studies at 1 month,6,9,13,16,21,22,25,27,30 5 studies at 6
months,6,9,13,16,21 and 3 studies at 12 months.6,9,16 Accord-
ing to this information, there was no significant deterioration
in echocardiographic measurements during the assessment
period. Death rate at 6 months postprocedure ranged from
18% to 48%.6,9,11,16,18,20,21,25 One study by Cribier and col-
leagues6 reported that at 6 months, 16 of 27 patients (60%)gery c June 2010
Conversion to
valvuloplasty,
n (%)
Vascular
complications,
n (%)
Paravalvular
leak>2þ,
n (%)
Valve-in-valve
procedure,
n (%)
Aortic dissection/
perforation,
n (%)
Transfusion>2 U,
n (%)
Procedural
duration,
hours ± SD
Length
of stay,
days ± SD
— — 5 (15) — — — — —
— 6 (12) 3 (6) — 1 (2) 9 (18) — 5y
— 2 (17) 4 (33) — — 2 (17) 2.9  1.2 17  8
— 1 (8) 1 (8) 1 (8) — — — 8  2
— 0 4 (18) 1 (5) — 1 (5) — 7  3
0 — 1 (4) 1 (4) — 3 (12) — 9  5
— — — — 1 (2) — — —
— 2 (8) 6 (23) — 1 (4) — 2.5  1.5 —
— — 3 (5) — — — 2.5  1.5 —
— — 14 (35) — — 1 (3) — —
1 (4) — 2 (8) — 0 6 (24) — —
— 1 (8) — — — — 1.8–2.3y 3–5y
— — — — — 2 (18) .5y 13.5y
— — — 4 (12) — — — —
0 5 (17) 2 (7) 1 (3) 0 — 1.0  0.3 —
2 (2) — — 2 (2) 0 — 2.9  1.1 —
— 12 (2) — 17 (3) 4 (1) — 2y —
TABLE 3. Continued
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of their patients was reported in a subsequent paper.7 One
patient died at 10 months (reason unknown) and another at
30 months (renal failure). Ten patients were followed for
at least 1 year, 4 of them for 2 years, and 2 of them for 3
years.
Svensson and associates21 reported on a Food and Drug
Administration–approved feasibility study incorporating
40 patients treated with a transapical inserted the Edwards
equine or bovine valve. This is the only published study re-
porting on quality-of-life data. Quality-of-life scores im-
proved from preoperatively (SF-12 Physical 28.7, standard
deviation 6.1; Mental 48.1, standard deviation 11.5) to post-
operatively at 6 months (SF-12 Physical 35.2, standard devi-
ation 7.4; Mental 50.4, standard deviation 11.7). The
physical improvement was significant (P ¼ .002).
DISCUSSION
With the population aging, AS is becoming a more prev-
alent public health issue. Medical therapy is unlikely to mod-
ify the course of the disease, especially once symptoms or
left ventricular dysfunction become manifest. Percutaneous
balloon aortic valvuloplasty has only a limited role in the
treatment of AS, as the results are not durable. Surgical
AVR remains the mainstay of definitive treatment.3 Al-
though surgical therapy is effective, it entails the risks and
morbidity associated with cardiopulmonary bypass and
median sternotomy. When a frail and elderly patient withThe Journal of Thoracic and Carsignificant comorbidities presents with severe AS, he or
she may be precluded from surgical AVR due to potentially
high operative risks. TAV implantation with its less invasive
nature is believed to offer a safer treatment solution for these
patients.35
In the current literature, no randomized controlled trials
have compared TAV implantation with conservative medi-
cal treatment, balloon valvuloplasty, or standard AVR.
The clinical experience with TAV is substantiated mainly
by short-term results. There is an ongoing randomized trial
(Placement of AoRTic TraNscathetER Valve trial in the
U.S. [PARTNER US]; ClinicalTrials.gov identifier
NCT00530894) using this valve comparing TAV implanta-
tion versus surgical AVR in patients at high surgical risk and
TAV implantation versus medical treatment or balloon aor-
tic valvuloplasty in patients at extreme surgical risk. The
present systematic review based on the available observa-
tional series demonstrated the following key points. First,
in view of the feasibility and safety results of TAV implan-
tation, the procedure success rate ranged from 74% to 100%
but there is a potential for serious complications. The 30-day
mortality (0%–25%), 30-day MACCE (range 3%–35%),
and 6-month mortality (18%–48%) were high, especially
in the initial reports.6,21,22,30 Without randomized trials, it
is not clear whether the high interventional mortality risk as-
sociated with TAV insertion is lower than the risk associated
with conventional surgery. The procedural and short-term
outcomes appeared to be improving in more recent studiesdiovascular Surgery c Volume 139, Number 6 1525
TABLE 4. Echocardiography measurements and clinical data following transcatheter aortic valve implantation
Study n
Mean aortic
valve area before
TAV (cm2) ± SD
Mean aortic
valve area after
TAV (cm2) ± SD
Peak pressure gradient
before TAV
(mm Hg) ± SD
Peak pressure gradient
after TAV
(mm Hg) ± SD
Mean pressure gradient
before TAV
(mm Hg) ± SD
Antegrade Edwards valve
Rouen6 33 0.6  0.1 1.7  0.1 — — 37  13
Retrograde Edwards valve
Vancouver9 50 0.6  0.2 1.7  0.4 — — 46  17
Paris11 12 0.5  0.1 1.7  0.5 — — 50  19
Athens12 12 0.6  0.1 1.8  0.1 91  33 22  7 57  23
Quebec13 22 0.6  0.2 1.5  0.3 56  15 17  5 34  10
Transapical Edwards valve
Vancouver16 26 0.5  0.1 1.7  0.5 — — 45  14
Leipzig18 50 — — — 15  7 —
Frankfurt19 26 0.6  0.1 — — — —
Multicenter20 59 0.5  0.2 — — 18  11 —
Bicenter21 40 0.6  0.1 1.6  0.4 65  15 15  5 40  10
Retrograde CoreValve valve
Siegburg22 25 0.7  0.1 — 70  14 21  5 44  11
Brighton23 12 — — — — —
Montreal25 11 0.6  0.2 1.3  0.4 — — 51  19
Rotterdam27 33 0.8  0.2 2.0  0.9 77  28 20  12 46  16
Catania29 30 0.6  0.2 1.5  0.4 86  22 — 58  18
Multicenter30 86 0.6  0.2 — 71  23 — 44  15
Multicenter31 646 0.6  0.2 — 78  26 — 49  14
TAV, Transcatheter aortic valve; NYHA, New York Heart Association; SD, standard deviation.
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Acquired Cardiovascular Disease Yan et alwith accumulating number of patients. In the earlier reports,
Cribier and colleagues6 reported a procedural success rate of
82% in 33 patients received Cribier-Edwards prosthesis.6
Grube and collaborators22 obtained a procedural success
rate of 84% using the first- and second-generation Core-
Valve devices. Webb and colleagues9 demonstrated proce-
dural success increased from 76% in the first 25 patients
to 96% in the subsequent 25 patients and an associated de-
crease in 30-day mortality from 16% to 8%, respectively. In
a recent multicenter study on 646 patients receiving the
third-generation CoreValve, the overall procedural success
rate was 97%, and the 30-day all-cause mortality was
8%.31 Main aspects of the learning curve for TAV interven-
tion are device technology, procedural skills, and decision
making involving case selection, intraprocedural strategic
plans, and alterations as well as decision making in manage-
ment of complications. At this stage, the number of patients
required to regard a specialized center well trained is not cer-
tain. This procedure requires a high level of training, expertise,
and infrastructure to optimize safety for both staff and patients.
Therefore, concentration of the services at centers with expe-
rience is likely to increase quality of care for these patients.
Second, the short-term efficacy based on echocardiogra-
phy measurements and NYHA functional class for patients
who had successful TAV, irrespective of the procedural ap-
proach used, seems to be encouraging. Based on the limited
data available, echocardiography measurements at 1-, 6-,
and 12-month follow-up did not demonstrate significant1526 The Journal of Thoracic and Cardiovascular Surfunctional deterioration. However, long-term follow-up
data are not available and the durability of the prostheses
is uncertain. Assessment of the long-term durability will
require at least 5 years of follow-up. Given the limited life
expectancy of patients currently considered for TAV, this
may not be practical. It is also noted that although there
are significant improvements in valve hemodynamic perfor-
mance and echocardiography findings, impact on patients’
quality of life is less clear.
Currently, TAV is restricted to elderly patients who are
considered at very high risk for conventional surgery. In
a joint position statement published in 2005, the Society
of Thoracic Surgeons, the American Association for Tho-
racic Surgery, and the Society for Cardiovascular Angiog-
raphy and Interventions cautioned against the widespread
use of these technologies without proper evaluation.36 In
the absence of published guidelines, the selection of cases
must be multidisciplinary. All studies evaluated aimed to
recruit patients at ‘‘high surgical risk’’ or ‘‘nonsurgical’’
candidates with AS. The eligibility of patients for TAV
is poorly defined or not reported in 4 studies,9,13,16,23
and in the other studies, the operability is mostly based
on assessment by clinicians, supplemented with informa-
tion obtained from an operative risk score, mostly the
EuroSCORE, which provides an estimation of the opera-
tive mortality risk.
However, the validity of this risk tool for estimating the
surgical risk incurred by high-risk patients has beengery c June 2010
Mean pressure gradient
after TAV
(mm Hg) ± SD
LV ejection
fraction before
TAV (%) ± SD
LV ejection
fraction after
TAV (%) ± SD
NYHA functional
class improved
vs baseline, n (%)
Patients at risk at
6-mo follow-up,
n (%)
Patients at risk at
12-mo follow-up,
n (%)
Death at
6 mo, n (%)
9  2 45  18 53  14 21 (64) 11 (33) 5 (15) 16 (48)
11  5 53  15 57  13 25 (50) 35 (70) 17 (34) 9 (18)
11  3 47  16 — 7 (58) 9 (75) — 3 (25)
10  3 — — 12 (100) — — —
9  3 51  16 54  11 17 (77) 10 (45) — —
9  5 56  13 63  9 Most 17 (65) 17 (65) 9 (35)
7  4 53  14 — — 37 (74) 36 (72) 13 (26)
6  2 — — — — — —
9  6 47  16 — — 15 (25) 5 (8) 13 (22)
8  3 52  15 55  19 — — — 13 (33)
12  3 54  16 — 18 (72) 7 (28) 2 (8) —
— — — — — — —
9  4 49  17 56  11 11 (100) 1 (9) 1 (9) 5 (45)
12  7 41  12 46  15 — — — —
9  4 53  8 — — 13 (43) 5 (17) —
9 54  16 — — — — —
3  2 52  14 — — — — —
TABLE 4. Continued
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Yan et al Acquired Cardiovascular Diseasecriticized. Recent observational data indicate that the Euro-
SCORE severely overestimates operative risk in high-risk
patients having isolated surgical AVR.37,38 In surgical series
from the Mayo Clinic, an estimated 30-day mortality of
23.6% was significantly higher than an observed mortality
of only 5.8%.37 By comparison, Cribier and associates6
enrolled patients with a mean predicted operative risk of
12  2 for TAV implantation and experienced a 30-day
mortality of 18%.6 Grube and colleagues30 conducted
a multi-institutional study using the CoreValve percutane-
ous aortic valve on 86 patients with a EuroSCORE of 22
 13 and achieved 30-day mortality of 12%. This implies
that patients with AS who are considered at high risk for
conventional AVR may actually present lower mortality
rates if treated surgically than if treated by means of TAV
insertion. Clinicians must be cautious in estimating opera-
tive risk from models that were not intended for this specific
use. The definition of ‘‘high surgical risk’’ is difficult, as
evidenced by the conversion of such patients to open
AVR after failure of TAV implantation. In the multicenter
study by Grube and colleagues,30 6 patients required emer-
gency conversion to open procedure to retrieve the devices
and successfully implanted aortic prostheses with only 1
operative death.
We attempted to evaluate the durability of TAV, but there
is a lack of comparative studies and the data on long-term ef-
ficacy and durability of TAV in the current literature. The
relatively unproven nature and inherent risks of this new
therapy mandate a formal team approach to patient selectionThe Journal of Thoracic and Carand outcome analysis. The inclusion and exclusion criteria
of the PARTNER trial provide some indication of the limits
of this new technology. Before further convincing evidence
becomes available, the use of TAV implantation should be
considered only within the boundaries of clinical trials
with special arrangements for clinical governance, consent,
and audit or research. Decision on eligibility must be indi-
vidualized and assessed by a multidisciplinary team of car-
diologists, cardiac surgeons, and cardiac anesthesiologists.
It is likely that progressive development of technology, fa-
miliarity with techniques, and better understanding of appro-
priate criteria for patient selection will continue to refine the
indications for TAV procedures.References
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